OBJECT: The purpose of this study was to evaluate the effect on tumor growth and symptom relief in patients with jugular foramen schwannomas after undergoing gamma knife radiosurgery (GKS). METHODS: Between November 1993 and December 2000, 27 patients were treated for jugular foramen schwannomas. The results of GKS in these cases are reviewed. Twelve patients had undergone previous tumor resection and the others underwent GKS as their primary treatment. The mean tumor volume was 13.5 cm3 (range 4.7-35.7 cm3). The mean margin dose was 14.6 Gy (range 9.8-20 Gy). The mean maximum dose was 32.6 Gy (range 25.4-50 Gy). The prescription isodose was 35 to 55%. Twenty-five patients were followed for a mean period of 38.7 months (range 9-90 months). Tumors shrank in 11 patients, remained stable in 13, and enlarged in one patient who underwent a second GKS procedure. Sixteen patients improved and nine remained at their pre-GKS clinical status. No patient developed new cranial nerve deficits after GKS. CONCLUSIONS: The follow-up results indicate that GKS is a safe and effective primary or adjuvant treatment method for the control of jugular foramen schwannomas.
OBJECT: The purpose of this study was to evaluate the effect on tumor growth and symptom relief in patients with jugular foramen schwannomas after undergoing gamma knife radiosurgery (GKS). METHODS: Between November 1993 and December 2000, 27 patients were treated for jugular foramen schwannomas. The results of GKS in these cases are reviewed. Twelve patients had undergone previous tumor resection and the others underwent GKS as their primary treatment. The mean tumor volume was 13.5 cm3 (range 4.7-35.7 cm3). The mean margin dose was 14.6 Gy (range 9.8-20 Gy). The mean maximum dose was 32.6 Gy (range 25.4-50 Gy). The prescription isodose was 35 to 55%. Twenty-five patients were followed for a mean period of 38.7 months (range 9-90 months). Tumors shrank in 11 patients, remained stable in 13, and enlarged in one patient who underwent a second GKS procedure. Sixteen patients improved and nine remained at their pre-GKS clinical status. No patient developed new cranial nerve deficits after GKS. CONCLUSIONS: The follow-up results indicate that GKS is a safe and effective primary or adjuvant treatment method for the control of jugular foramen schwannomas.
Authors: Rawee Ruangkanchanasetr; John Y K Lee; Suneel N Nagda; Geoffrey A Geiger; James D Kolker; Douglas C Bigelow; Michael J Ruckenstein; MacLean Nasrallah; Michelle Alonso-Basanta Journal: J Neurol Surg B Skull Base Date: 2018-05-10
Authors: Young Goo Kim; Chang Kyu Park; Na Young Jung; Hyun Ho Jung; Jong Hee Chang; Jin Woo Chang; Won Seok Chang Journal: Radiat Oncol Date: 2022-05-07 Impact factor: 4.309